Sanara Medtech Inc
NASDAQ:SMTI
Sanara Medtech Inc
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 63 full-time employees. The Company’s products include surgical wound care products, which includes CellerateRX Surgical Activated Collagen (Powder and Gel), and chronic wound care products, which include HYCOL Hydrolyzed Collagen (Powder and Gel), BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel. The surgical wound care products are used in specialties including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, oncology, plastic/reconstructive, podiatric, urology and vascular. The chronic wound care products are used across the post-acute continuum of care, including home health, hospice, physician offices, podiatrists, retail, skilled nursing facilities, and wound care centers.
Revenue Growth: Sanara MedTech's Surgical business delivered Q3 net revenue of $26.3 million, up 22% year-over-year, driven mainly by soft tissue repair products.
Gross Margin Improvement: Gross margin rose by 200 basis points to 93%, supported by strong sales mix.
Profitability Gains: Operating income reached $2.9 million (up 278% YoY) and net income from continuing operations was $800,000, a $1 million improvement from last year.
THP Discontinuation: Management decided to cease Tissue Health Plus (THP) operations after failing to find a partner, focusing resources on the core Surgical business.
Operating Leverage: Strong sales growth achieved without increasing headcount; operating leverage is visible in improved EBITDA.
Q4 Revenue Outlook: Q4 revenue is expected to grow in the high single digits to low teens YoY, after adjusting for one-time benefits last year.
Cash Flow: The company generated $2.2 million of net cash from operating activities and expects no material cash spend on THP after 2025.
